CHIMERIX INC
CMRXHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $212,000 | $324,000 | $33.8M | $2.0M | $5.4M | $12.5M |
| Operating income | −$96.6M | −$93.1M | −$60.4M | −$173.4M | −$44.5M | −$116.0M |
| Net income | −$88.4M | −$82.1M | $172.2M | −$173.2M | −$43.5M | −$112.6M |
| Total assets | $146.0M | $212.8M | $279.3M | $100.5M | $84.7M | $119.4M |
| Total liabilities | $24.3M | $19.7M | $22.5M | $32.3M | $11.3M | $9.4M |
| Equity | $121.7M | $193.0M | $256.9M | $68.3M | $73.4M | $110.0M |
| EPS (diluted) | $-0.99 | $-0.93 | $1.94 | $-2.04 | $-0.70 | $-2.03 |
| Shares out. | 89.2M | 88.3M | 87.0M | 85.7M | 61.7M | 50.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −45550.5%
- Net margin
- −41692.0%
- Return on equity
- −72.6%
- Return on assets
- −60.5%
- Return on capital (ROCE)
- −79.1%
- Liabilities / assets
- 16.7%
- Debt / equity
- 0.20×
- Book value / share
- $1.36
- Revenue growth (YoY)
- −34.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -13.89distress
- Accruals / assets
- −9.2%clean
- Beneish M-Score
- 15.48elevated
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- MODEYSOAug 6, 2025
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Sherman Michael A.Officer — Chief Executive Officer | Apr 21, 2025 | D | 87,000 | $8.55 |
| Riga Thomas JOfficer — COO and CCO | Apr 21, 2025 | D | 60,828 | $8.55 |
| Middleton Fred ADirector | Apr 21, 2025 | D | 40,000 | $8.55 |
| Meyer Robert J.Director | Apr 21, 2025 | D | 35,150 | $8.55 |
| Melemed Allen S.Officer — CHIEF MEDICAL OFFICER | Apr 21, 2025 | D | 173,852 | $8.55 |
| Laspaluto MichelleOfficer — CHIEF FINANCIAL OFFICER | Apr 21, 2025 | D | 181,541 | $8.55 |
| Jakeman DavidOfficer — VP OF FINANCE AND ACCOUNTING | Apr 21, 2025 | D | 156,209 | $8.55 |
| Demski Martha JDirector | Apr 21, 2025 | D | 72,055 | $8.55 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Apr 15, 2025 | 1.6M | 1.0 | -52.6% |
| Mar 31, 2025 | 3.4M | 2.2 | -0.7% |
| Mar 14, 2025 | 3.4M | 1.0 | -27.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 21, 2025
- Results of operationsMar 21, 2025
- Entered a material agreement · Regulation FD disclosureMar 5, 2025
- Other material eventMar 3, 2025
- Entered a material agreement · New financial obligation · Other material eventDec 30, 2024
- Regulation FD disclosure · Other material eventDec 10, 2024
- Director / officer changeNov 14, 2024
- Results of operations · Regulation FD disclosureNov 7, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AAug 13, 2025
- SCHEDULE 13G/AMay 15, 2025
- SCHEDULE 13GMay 9, 2025
- 15-12GMay 1, 2025
- EFFECTApr 22, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025
- S-8 POSApr 21, 2025